Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C

TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: review decision - December 2013 information

TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 112 KB)

TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: review proposal - October 2013 information

TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: Appendix A - provisional matrix of stakeholders (PDF 100 KB)

TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: Appendix B - GE Proposal Paper September 2013 (PDF 534 KB)

Review decision, August 2008 information

Review decision - March 2008: table of comments (PDF 135 KB)

Review proposal, March 2008 information

TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: distribution list (PDF 46 KB)

People with chronic hepatitis C to benefit from guidance on new drugs and treatments  information

People with chronic hepatitis C to benefit from guidance on new drugs and treatments (PDF 99 KB)

Health technology assessment: interferon alpha (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C (PDF 863 KB)

Final Appraisal Determination - Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C information

Final Appraisal Determination (PDF 303 KB)

Appraisal Consultation Document: Interferon alpha (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C information

Health Technology Assessment: Interferon alpha (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C (PDF 863 KB)

Protocol for Pegylated interferon alpha 2a and alpha 2b in the treatment of chronic hepatitis C (PDF 274 KB)

Scope: Pegylated interferon alpha 2a and alpha 2b for hepatitis C information